Anaveon raises CHF 35 million
Anaveon, an immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch, the healthcare accelerator of BaselArea.swiss in December 2017 and in 2018 also raised additional seed money from the UZH Life Sciences Fund.
Anaveon is developing a selective interleukin-2 receptor (IL-2 receptor) agonist to fuel a patient’s immune system to respond to tumors. The naturally occurring IL-2 receptor stimulates a type of immune cell called a T-cell to attack tumors. Il-2 is already being used for the treatment of cancer. However, there are side effects and dose limiting toxicities associated with IL-2 therapy. Anaveon’s approach plans to overcome these challenges and the proceeds of the Series A financing will now enable further development of its lead compound, as announced in a press release.
Anaveon was founded by Onur Boyman, Professor and Chair in the Department of Immunology at the University of Zurich (UZH), and Andreas Katopodis. Prior to this, Andreas Katopodis was Director of Autoimmunity, Transplantation and Inflammatory Disease at the Novartis Institutes for BioMedical Research.
Share this article
You might also be interested in
The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...Read More
The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...Read More
The COVID-19 pandemic has hit economies worldwide – and we have not yet overcome it. However, Switzerland is among the...Read More
The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...Read More
The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...Read More